Recombinant Urate Oxidase Manufacturing

• 

  Manufacturing Recombinant Urate Oxidase at Scale

  After the desired protein is successfully produced in the host cells, it must be extracted and purified on a large scale. Such a strategy would also require extensive purification, using more sophisticated machinery and additional steps including centrifugation (a spin step that separates based on density), filtration (to remove particulates), and chromatography to further purify the proteins.

• 

  Challenges and Opportunities in Recombinant Urate Oxidase Manufacturing

  But as we face long lines, crowds and various other frustrations there are also many, oh so many beautiful things on the horizon. The manufacturing process is being facilitated more than ever before with the help of new trends and innovative technologies. Researchers are also working on new strategies to ensure quality control and decrease production costs in order to make this vital protein more accessible.

• 

  The Future of Recombinant Manufacturing Techniques

  The future of recombinant protein synthesis which is the next step to fulfilling our demands, seems very bright as there are already new techniques and studies being developed. Recent advancements like CRISPR-Cas9, a gene-editing technology tool have found their way to researchers' labs giving them the possibility of creating personalized gene sequences that can bring about better protein yield.

Why choose Yaohai Recombinant Urate Oxidase Manufacturing?

• Qualitätssystem und Einhaltung globaler Vorschriften

  Yaohai BioPharma is a Top 10 Microbial CDMO that integrates quality management and regulatory affairs. We have a quality management system that is in compliance with current Recombinant Urate Oxidase Manufacturing and regulations around the globe. Our regulatory team is knowledgeable in the global regulatory frameworks that help accelerate biological launches. We ensure traceable production procedures quality products, as well as in compliance with the guidelines of the US FDA and EU EMA. Australia TGA and China NMPA are also in compliance. Yaohai BioPharma has successfully passed the on-site audit by the European Union's qualified Person (QP) for our GMP quality system and production site. We also successfully cleared the first certification audits of the ISO9001 Quality Management System and ISO14001 Environmental Management System.

• Fachkompetenz und langjährige Erfahrung

  Yaohai Bio-Pharma is a leading in microbial biologics CDMO. Our main focus has been the production of microbial vaccinations and therapeutics to manage the health of pets, humans and animals. health. We have modern RD and manufacturing technology platforms that cover the entire process, from microbial strain engineering, cell banking, process and method design to commercial and clinical manufacturing, which ensures the success supply of the most cutting-edge solutions. Through the years we have gained vast expertise in using microbial sources. Over 200 projects were successfully completed. In addition, we support our clients in get through regulations, such as those of the US FDA as well as EU EMA. We also help them to navigate Australia TGA and China NMPA. Our expert knowledge and vast experience allow us to quickly respond to market demands and provide Recombinant Urate Oxidase Manufacturing CDMO services.

• Anpassung, Effizienz und Kosteneffizienz

  Yaohai Bio-Pharma is experienced in biologicals derived from microbial sources. We provide customized RD solutions and manufacturing, while minimising potential risks. We have worked on various modalities, including recombinant subunit vaccines, peptides hormones, cytokines growth factors, single-domain antibodies enzymes, plasmid DNA various mRNAs, and more. We have specialized in multiple microorganisms, including Recombinant Urate Oxidase Manufacturing intracellular and extracellular secretion (yields up to 15g/L) and intracellular soluble bacteria and inclusion body (yields up to 10g/L). We have also established a BSL-2 fermentation platform to create bacteria-based vaccines. We are experts in improving processes, boosting product yields, and decreasing production costs. We have a highly efficient technology team that ensures timely and top-quality project delivery. This allows us to bring your unique products faster to market.

• Robuste Lieferkette und Fertigungskapazitäten

  Yaohai Bio-Pharma, a top 10 producer of Recombinant Urate Oxidase Manufacturing, specializes in microbial fermentation. We have set up a modern facility with advanced facilities as well as robust RD manufacturing capabilities. Five production lines for drug substances complying with GMP standards for microbial purification and ferment along with two automated fill and finish lines for vials as well as cartridges as well as pre-filled needles are readily available. The available fermentation scales range between 100L and 2000L. Vial filling specifications cover 1ml - 25ml. the pre-filled cartridge or syringe filling specifications are between 1-3ml. The production workshop is cGMP certified and offers the availability of commercial and clinical samples. Our plant produces big molecules that are exported to all over the world.

Verwandte Produktkategorien

• Bioproduktion von rekombinantem Schweineinsulin
• GMP-Herstellung rekombinanter Peptide
• Produktionsprozess für rekombinantes menschliches Kollagen
• Herstellung von rekombinantem IGF-1
• Herstellung rekombinanter Leptine
• Rekombinante Midkine-Herstellung
• Herstellung rekombinanter Parkin-Proteine
• Herstellung rekombinanter Tumorantigene
• Herstellung von rekombinantem Kollagen Typ 17
• Herstellung von rekombinantem Kollagen Typ I

Finden Sie nicht, was Sie suchen?
Kontaktieren Sie unsere Berater für weitere verfügbare Produkte.